This story originally ran on Oct. 20.

By Adam Bonislawski

Somalogic said this week that it has signed a multi-year research agreement with Novartis to use its aptamer-based proteomics platform to aid the pharma firm's drug discovery and development efforts.

The company also announced this week the launch of its new Somaplex Standard product, a panel of 288 assays targeting 287 proteins of interest that it will make available as a research tool for pharma, biotech, and academic clients.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.